Chemopreventive Effects of Licorice and Its Components

Current Pharmacology Reports

Volumn 1, Issue 1, 2015, Pages 60-71

  Bode, Ann M ^a   Dong, Zigang ^a  

^a University of Minnesota Hormel Institute   (United States)

Author keywords

Glycyrrhetic acid; Glycyrrhizic acid; Iso liquiritigenin; Isoangustone A; Licochalcone A; Licochalcone E

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ACETYLCYSTEINE; CASPASE 3; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE 1; FAS LIGAND; FLAVONOID; GLUTATHIONE; GLYCYRRHETINIC ACID; GLYCYRRHIZIC ACID; HEAT SHOCK PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 23; ISOANGUSTONE A; LICOCHALCONE A; LICOCHALCONE E; LIPID PEROXIDASE; LIPOPOLYSACCHARIDE; LIQUIRITIGENIN; MICROTUBULE ASSOCIATED PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PLANT MEDICINAL PRODUCT; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; AUTOPHAGY; CELL CYCLE REGULATION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; COLON CANCER; COLON TUMOR; DOWN REGULATION; GLYCYRRHIZA; HUMAN; LIVER METASTASIS; MOLECULAR DYNAMICS; NEOPLASM; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; TRANSCRIPTION REGULATION;

EID: 85017046797     PISSN: None     EISSN: 2198641X     Source Type: Journal    
DOI: 10.1007/s40495-014-0015-5     Document Type: Review

References (117)

1. Shibata S. A drug over the millennia: pharmacognosy, chemistry, and pharmacology of licorice. Yakugaku Zasshi. 2000;120(10):849–62.
2. Gibson MR. Glycyrrhiza in old and new perspectives. Lloydia. 1978;41(4):348–54.
3. GRAS status of licorice (Glycyrrhiza), ammoniated glycyrrhizin, and monoammonium glycyrrhizinate, Fed Reg 50 (1985).
4. Johns C. Glycyrrhizic acid toxicity caused by consumption of licorice candy cigars. Cjem. 2009;11(1):94–6.
5. Spinks EA, Fenwick GR. The determination of glycyrrhizin in selected UK liquorice product. Food Addit Contam. 1990;7(6):769–78.
6. Ibsen KK. Liquorice consumption and its influence on blood pressure in Danish school-children. Dan Med Bull. 1981;28(3):124–6.
7. Gomez-Sanchez EP, Gomez-Sanchez CE. Central hypertensinogenic effects of glycyrrhizic acid and carbenoxolone. Am J Physiol. 1992;263(6 Pt 1):E1125–30.
8. Sigurjonsdottir HA, Franzson L, Manhem K, Ragnarsson J, Sigurdsson G, Wallerstedt S. Liquorice-induced rise in blood pressure: a linear dose–response relationship. J Hum Hypertens. 2001;15(8):549–52.
9. Fukai T, Marumo A, Kaitou K, Kanda T, Terada S, Nomura T. Anti-Helicobacter pylori flavonoids from licorice extract. Life Sci. 2002;71(12):1449–63.
10. Wang ZY, Nixon DW. Licorice and cancer. Nutr Cancer. 2001;39(1):1–11.
11. Fuhrman B, Volkova N, Kaplan M, Presser D, Attias J, Hayek T, et al. Antiatherosclerotic effects of licorice extract supplementation on hypercholesterolemic patients: increased resistance of LDL to atherogenic modifications, reduced plasma lipid levels, and decreased systolic blood pressure. Nutrition. 2002;18(3):268–73.
12. Asl MN, Hosseinzadeh H. Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytother Res. 2008;22(6):709–24.
13. Draelos ZD. Skin lightening preparations and the hydroquinone controversy. Dermatol Ther. 2007;20(5):308–13.
14. Kusano A, Nikaido T, Kuge T, Ohmoto T, Delle Monache G, Botta B, et al. Inhibition of adenosine 3′,5′-cyclic monophosphate phosphodiesterase by flavonoids from licorice roots and 4-arylcoumarins. Chem Pharm Bull. 1991;39(4):930–3.
15. Vaya J, Belinky PA, Aviram M. Antioxidant constituents from licorice roots: isolation, structure elucidation and antioxidative capacity toward LDL oxidation. Free Radic Biol Med. 1997;23(2):302–13.
16. Hatano T, Shintani Y, Aga Y, Shiota S, Tsuchiya T, Yoshida T. Phenolic constituents of licorice. VIII. Structures of glicophenone and glicoisoflavanone, and effects of licorice phenolics on methicillin-resistant Staphylococcus aureus. Chem Pharm Bull. 2000;48(9):1286–92.
17. Nomura T, Fukai T. Phenolic constituents of licorice (Glycyrrhiza species). Fortschr Chem Org Naturst. 1998;73:1–158.
18. Hattori M, Sakamoto T, Yamagishi T, Sakamoto K, Konishi K, Kobashi K, et al. Metabolism of glycyrrhizin by human intestinal flora. II. Isolation and characterization of human intestinal bacteria capable of metabolizing glycyrrhizin and related compounds. Chem Pharm Bull. 1985;33(1):210–7.
19. Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH, Edwards CR. Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet. 1987;2(8563):821–4.
20. Whorwood CB, Sheppard MC, Stewart PM. Licorice inhibits 11 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid levels and potentiates glucocorticoid hormone action. Endocrinology. 1993;132(6):2287–92.
21. van Rossum TG, Vulto AG, Hop WC, Brouwer JT, Niesters HG, Schalm SW. Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial. J Gastroenterol Hepatol. 1999;14(11):1093–9.
22. Curreli F, Friedman-Kien AE, Flore O. Glycyrrhizic acid alters Kaposi sarcoma-associated herpesvirus latency, triggering p53-mediated apoptosis in transformed B lymphocytes. J Clin Invest. 2005;115(3):642–52.
23. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet. 2003;361(9374):2045–6.
24. Hoever G, Baltina L, Michaelis M, Kondratenko R, Tolstikov GA, Doerr HW, et al. Antiviral activity of glycyrrhizic acid derivatives against SARS-coronavirus. J Med Chem. 2005;48(4):1256–9.
25. Lee CH, Park SW, Kim YS, Kang SS, Kim JA, Lee SH, et al. Protective mechanism of glycyrrhizin on acute liver injury induced by carbon tetrachloride in mice. Biol Pharm Bull. 2007;30(10):1898–904.
26. Abe M, Akbar F, Hasebe A, Horiike N, Onji M. Glycyrrhizin enhances interleukin-10 production by liver dendritic cells in mice with hepatitis. J Gastroenterol. 2003;38(10):962–7.
27. Gumpricht E, Dahl R, Devereaux MW, Sokol RJ. Licorice compounds glycyrrhizin and 18beta-glycyrrhetinic acid are potent modulators of bile acid-induced cytotoxicity in rat hepatocytes. J Biol Chem. 2005;280(11):10556–63.
28. Shinada M, Azuma M, Kawai H, Sazaki K, Yoshida I, Yoshida T, et al. Enhancement of interferon-gamma production in glycyrrhizin-treated human peripheral lymphocytes in response to concanavalin A and to surface antigen of hepatitis B virus. Proc Soc Exp Biol Med. 1986;181(2):205–10.
29. Cherng JM, Lin HJ, Hung MS, Lin YR, Chan MH, Lin JC. Inhibition of nuclear factor kappaB is associated with neuroprotective effects of glycyrrhizic acid on glutamate-induced excitotoxicity in primary neurons. Eur J Pharmacol. 2006;547(1–3):10–21.
30. Agarwal R, Wang ZY, Mukhtar H. Inhibition of mouse skin tumor-initiating activity of DMBA by chronic oral feeding of glycyrrhizin in drinking water. Nutr Cancer. 1991;15(3–4):187–93.
31. Aydemir EA, Oz ES, Gokturk RS, Ozkan G, Fiskin K. Glycyrrhiza flavescens subsp. antalyensis exerts antiproliferative effects on melanoma cells via altering TNF-alpha and IFN-alpha levels. Food Chem Toxicol. 2011;49(4):820–8.
32. Kobayashi M, Fujita K, Katakura T, Utsunomiya T, Pollard RB, Suzuki F. Inhibitory effect of glycyrrhizin on experimental pulmonary metastasis in mice inoculated with B16 melanoma. Anticancer Res. 2002;22(6C):4053–8.
33. Cherng JM, Tsai KD, Yu YW, Lin JC. Molecular mechanisms underlying chemopreventive activities of glycyrrhizic acid against UVB-radiation-induced carcinogenesis in SKH-1 hairless mouse epidermis. Radiat Res. 2011;176(2):177–86. PubMed PMID: 21545294. Epub 2011/05/07. Eng. This group showed that ingesting orally licorice compounds could prevent UVB induced skin cancer, making it more applicable to the human condition.
34. Thirugnanam S, Xu L, Ramaswamy K, Gnanasekar M. Glycyrrhizin induces apoptosis in prostate cancer cell lines DU-145 and LNCaP. Oncol Rep. 2008;20(6):1387–92.
35. Hibasami H, Iwase H, Yoshioka K, Takahashi H. Glycyrrhizin induces apoptosis in human stomach cancer KATO III and human promyelotic leukemia HL-60 cells. Int J Mol Med. 2005;16(2):233–6.
36. Hibasami H, Iwase H, Yoshioka K, Takahashi H. Glycyrrhetic acid (a metabolic substance and aglycon of glycyrrhizin) induces apoptosis in human hepatoma, promyelotic leukemia and stomach cancer cells. Int J Mol Med. 2006;17(2):215–9.
37. Lin D, Zhong W, Li J, Zhang B, Song G, Hu T. Involvement of BID translocation in glycyrrhetinic acid and 11-deoxy glycyrrhetinic acid-induced attenuation of gastric cancer growth. Nutr Cancer. 2014;66(3):463–73.
38. Niwa K, Lian Z, Onogi K, Yun W, Tang L, Mori H, et al. Preventive effects of glycyrrhizin on estrogen-related endometrial carcinogenesis in mice. Oncol Rep. 2007;17(3):617–22.
39. Wang D, Wong HK, Feng YB, Zhang ZJ. 18beta-glycyrrhetinic acid induces apoptosis in pituitary adenoma cells via ROS/MAPKs-mediated pathway. J Neurooncol. 2014;116(2):221–30.
40. Rossi T, Castelli M, Zandomeneghi G, Ruberto A, Benassi L, Magnoni C, et al. Selectivity of action of glycyrrhizin derivatives on the growth of MCF-7 and HEP-2 cells. Anticancer Res. 2003;23(5A):3813–8.
41. Huang RY, Chu YL, Huang QC, Chen XM, Jiang ZB, Zhang X, et al. 18beta-Glycyrrhetinic acid suppresses cell proliferation through inhibiting thromboxane synthase in non-small cell lung cancer. PLoS ONE. 2014;9(4):e93690.
42. Song J, Ko HS, Sohn EJ, Kim B, Kim JH, Kim HJ, et al. Inhibition of protein kinase C alpha/betaII and activation of c-Jun NH2-terminal kinase mediate glycyrrhetinic acid induced apoptosis in non-small cell lung cancer NCI-H460 cells. Bioorg Med Chem Lett. 2014;24(4):1188–91.
43. Khan R, Khan AQ, Lateef A, Rehman MU, Tahir M, Ali F, et al. Glycyrrhizic acid suppresses the development of precancerous lesions via regulating the hyperproliferation, inflammation, angiogenesis and apoptosis in the colon of Wistar rats. PLoS ONE. 2013;8(2):e56020.
44. Chueh FS, Hsiao YT, Chang SJ, Wu PP, Yang JS, Lin JJ, et al. Glycyrrhizic acid induces apoptosis in WEHI-3 mouse leukemia cells through the caspase- and mitochondria-dependent pathways. Oncol Rep. 2012;28(6):2069–76.
45. Shintani S, Murase H, Tsukagoshi H, Shiigai T. Glycyrrhizin (licorice)-induced hypokalemic myopathy. Report of 2 cases and review of the literature. Eur Neurol. 1992;32(1):44–51.
46. Elinav E, Chajek-Shaul T. Licorice consumption causing severe hypokalemic paralysis. Mayo Clin Proc. 2003;78(6):767–8.
47. Mumoli N, Cei M. Licorice-induced hypokalemia. Int J Cardiol. 2008;124(3):e42–4.
48. Celik MM, Karakus A, Zeren C, Demir M, Bayarogullari H, Duru M, et al. Licorice induced hypokalemia, edema, and thrombocytopenia. Hum Exp Toxicol. 2012;31(12):1295–8.
49. Final report on the safety assessment of glycyrrhetinic acid, potassium glycyrrhetinate, disodium succinoyl glycyrrhetinate, glyceryl glycyrrhetinate, glycyrrhetinyl stearate, stearyl glycyrrhetinate, glycyrrhizic acid, ammonium glycyrrhizate, dipotassium glycyrrhizate, disodium glycyrrhizate, trisodium glycyrrhizate, methyl glycyrrhizate, and potassium glycyrrhizinate. Int J Toxicol. 2007;26 Suppl 2:79–112. PubMed PMID: 17613133. Epub 2007/12/06. eng.
50. Cuendet M, Guo J, Luo Y, Chen S, Oteham CP, Moon RC, et al. Cancer chemopreventive activity and metabolism of isoliquiritigenin, a compound found in licorice. Cancer Prev Res (Phila). 2010;3(2):221–32.
51. Ye L, Gho WM, Chan FL, Chen S, Leung LK. Dietary administration of the licorice flavonoid isoliquiritigenin deters the growth of MCF-7 cells overexpressing aromatase. Int J Cancer. 2009;124(5):1028–36.
52. Vandooren J, Van den Steen PE, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit Rev Biochem Mol Biol. 2013;48(3):222–72.
53. Ma J, Zhang Q, Chen S, Fang B, Yang Q, Chen C, et al. Mitochondrial dysfunction promotes breast cancer cell migration and invasion through HIF1alpha accumulation via increased production of reactive oxygen species. PLoS ONE. 2013;8(7):e69485.
54. Cao Y. VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs. Nat Rev Endocrinol. 2014;10(9):530–9.
55. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141(1):52–67.
56. Lorusso V, Marech I. Novel plant-derived target drugs: a step forward from licorice? Expert Opin Ther Targets. 2013;17(4):333–5.
57. Kang SW, Choi JS, Choi YJ, Bae JY, Li J, Kim DS, et al. Licorice isoliquiritigenin dampens angiogenic activity via inhibition of MAPK-responsive signaling pathways leading to induction of matrix metalloproteinases. J Nutr Biochem. 2010;21(1):55–65.
58. Lau GT, Ye L, Leung LK. The licorice flavonoid isoliquiritigenin suppresses phorbol ester-induced cyclooxygenase-2 expression in the non-tumorigenic MCF-10A breast cell line. Planta Med. 2010;76(8):780–5.
59. Takahashi T, Takasuka N, Iigo M, Baba M, Nishino H, Tsuda H, et al. Isoliquiritigenin, a flavonoid from licorice, reduces prostaglandin E2 and nitric oxide, causes apoptosis, and suppresses aberrant crypt foci development. Cancer Sci. 2004;95(5):448–53.
60. Zhao H, Zhang X, Chen X, Li Y, Ke Z, Tang T, et al. Isoliquiritigenin, a flavonoid from licorice, blocks M2 macrophage polarization in colitis-associated tumorigenesis through downregulating PGE2 and IL-6. Toxicol Appl Pharmacol. 2014;279(3):311–21. PubMed PMID: 25026504. Epub 2014/07/16. Eng. Showed different, interesting mechanism for the anticancer activity of iso-liquiritigenin.
61. Zhou Y, Ho WS. Combination of liquiritin, isoliquiritin and isoliquirigenin induce apoptotic cell death through upregulating p53 and p21 in the A549 non-small cell lung cancer cells. Oncol Rep. 2014;31(1):298–304.
62. Hsu YL, Chia CC, Chen PJ, Huang SE, Huang SC, Kuo PL. Shallot and licorice constituent isoliquiritigenin arrests cell cycle progression and induces apoptosis through the induction of ATM/p53 and initiation of the mitochondrial system in human cervical carcinoma HeLa cells. Mol Nutr Food Res. 2009;53(7):826–35.
63. Zheng H, Li Y, Wang Y, Zhao H, Zhang J, Chai H, et al. Downregulation of COX-2 and CYP 4A signaling by isoliquiritigenin inhibits human breast cancer metastasis through preventing anoikis resistance, migration and invasion. Toxicol Appl Pharmacol. 2014;280(1):10–20. PubMed PMID: 25094029. Epub 2014/08/06. Eng. This paper present a unique mechansim for the anticancer activity of iso-liquiritigenin.
64. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol. 1994;124(4):619–26.
65. Simpson CD, Anyiwe K, Schimmer AD. Anoikis resistance and tumor metastasis. Cancer Lett. 2008;272(2):177–85.
66. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153–66.
67. Sherr CJ. D-type cyclins. Trends Biochem Sci. 1995;20(5):187–90.
68. Sherr CJ. Cancer cell cycles. Science. 1996;274(5293):1672–7.
69. Huang W, Tang S, Qiao X, Ma W, Ji S, Wang K, et al. Isoangustone A induces apoptosis in SW480 human colorectal adenocarcinoma cells by disrupting mitochondrial functions. Fitoterapia. 2014;94:36–47.
70. Seon MR, Lim SS, Choi HJ, Park SY, Cho HJ, Kim JK, et al. Isoangustone A present in hexane/ethanol extract of Glycyrrhiza uralensis induces apoptosis in DU145 human prostate cancer cells via the activation of DR4 and intrinsic apoptosis pathway. Mol Nutr Food Res. 2010;54(9):1329–39.
71. Seon MR, Park SY, Kwon SJ, Lim SS, Choi HJ, Park H, et al. Hexane/ethanol extract of Glycyrrhiza uralensis and its active compound isoangustone A induce G1 cycle arrest in DU145 human prostate and 4T1 murine mammary cancer cells. J Nutr Biochem. 2012;23(1):85–92.
72. Lee E, Son JE, Byun S, Lee SJ, Kim YA, Liu K, et al. CDK2 and mTOR are direct molecular targets of isoangustone A in the suppression of human prostate cancer cell growth. Toxicol Appl Pharmacol. 2013;272(1):12–20. PubMed PMID: 23707764. Epub 2013/05/28. eng. One of the first papers to show direct molecular targets of a specific licorice compound.
73. Vlach J, Hennecke S, Amati B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J. 1997;16(17):5334–44.
74. Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med. 2002;8(10):1153–60.
75. Tsihlias J, Kapusta LR, DeBoer G, Morava-Protzner I, Zbieranowski I, Bhattacharya N, et al. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res. 1998;58(3):542–8.
76. Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, de Kernion JB, et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol. 1998;159(3):941–5.
77. Song NR, Lee EJ, Byun S, Kim JE, Mottamal M, Park JH, et al. Isoangustone A, a novel licorice compound, inhibits cell proliferation by targeting PI3-K, MKK4 and MKK7 in human melanoma. Cancer Prev Res (Phila). Oct 8. PubMed PMID: 24104352. Epub 2013/10/10. Eng. One of the first papers to report direct binding partners for a specific licorice compound.
78. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer. 2011;11(8):558–72.
79. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353(20):2135–47.
80. Willems L, Tamburini J, Chapuis N, Lacombe C, Mayeux P, Bouscary D. PI3K and mTOR signaling pathways in cancer: new data on targeted therapies. Curr Oncol Rep. 2012;14(2):129–38.
81. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008;27(41):5497–510.
82. Takahashi-Yanaga F, Sasaguri T. GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy. Cell Signal. 2008;20(4):581–9.
83. Xiao XY, Hao M, Yang XY, Ba Q, Li M, Ni SJ, et al. Licochalcone A inhibits growth of gastric cancer cells by arresting cell cycle progression and inducing apoptosis. Cancer Lett. 2011;302(1):69–75.
84. Rafi MM, Rosen RT, Vassil A, Ho CT, Zhang H, Ghai G, et al. Modulation of bcl-2 and cytotoxicity by licochalcone-A, a novel estrogenic flavonoid. Anticancer Res. 2000;20(4):2653–8.
85. Kim YJ, Jung EB, Myung SC, Kim W, Lee CS. Licochalcone A enhances geldanamycin-induced apoptosis through reactive oxygen species-mediated caspase activation. Pharmacology. **;92(1–2):49–59. PubMed PMID: 23921841. Epub 2013/08/08. eng.
86. Lee CS, Kwak SW, Kim YJ, Lee SA, Park ES, Myung SC, et al. Guanylate cyclase activator YC-1 potentiates apoptotic effect of licochalcone A on human epithelial ovarian carcinoma cells via activation of death receptor and mitochondrial pathways. Eur J Pharmacol. 2012;683(1–3):54–62.
87. Kim YH, Shin EK, Kim DH, Lee HH, Park JH, Kim JK. Antiangiogenic effect of licochalcone A. Biochem Pharmacol. 2010;80(8):1152–9.
88. Park SY, Kim EJ, Choi HJ, Seon MR, Lim SS, Kang YH, et al. Anti-carcinogenic effects of non-polar components containing licochalcone A in roasted licorice root. Nutr Res Pract. 2014;8(3):257–66.
89. Yo YT, Shieh GS, Hsu KF, Wu CL, Shiau AL. Licorice and licochalcone-A induce autophagy in LNCaP prostate cancer cells by suppression of Bcl-2 expression and the mTOR pathway. J Agric Food Chem. 2009;57(18):8266–73.
90. Kim JS, Park MR, Lee SY, Kim K, Moon SM, Kim CS, et al. Licochalcone A induces apoptosis in KB human oral cancer cells via a caspase-dependent FasL signaling pathway. Oncol Rep. 2014;31(2):755–62.
91. Fu Y, Hsieh TC, Guo J, Kunicki J, Lee MY, Darzynkiewicz Z, et al. Licochalcone-A, a novel flavonoid isolated from licorice root (Glycyrrhiza glabra), causes G2 and late-G1 arrests in androgen-independent PC-3 prostate cancer cells. Biochem Biophys Res Commun. 2004;322(1):263–70.
92. Park JH, Lim HJ, Lee KS, Lee S, Kwak HJ, Cha JH, et al. Anti-proliferative effect of licochalcone A on vascular smooth muscle cells. Biol Pharm Bull. 2008;31(11):1996–2000.
93. Kim JK, Shin EK, Park JH, Kim YH. Antitumor and antimetastatic effects of licochalcone A in mouse models. J Mol Med (Berl). 2010;88(8):829–38.
94. Lee CK, Son SH, Park KK, Park JH, Lim SS, Kim SH, et al. Licochalcone A inhibits the growth of colon carcinoma and attenuates cisplatin-induced toxicity without a loss of chemotherapeutic efficacy in mice. Basic Clin Pharmacol Toxicol. 2008;103(1):48–54.
95. Kwon HS, Park JH, Kim DH, Kim YH, Shin HK, Kim JK. Licochalcone A isolated from licorice suppresses lipopolysaccharide-stimulated inflammatory reactions in RAW264.7 cells and endotoxin shock in mice. J Mol Med (Berl). 2008;86(11):1287–95.
96. Furuhashi I, Iwata S, Shibata S, Sato T, Inoue H. Inhibition by licochalcone A, a novel flavonoid isolated from liquorice root, of IL-1beta-induced PGE2 production in human skin fibroblasts. J Pharm Pharmacol. 2005;57(12):1661–6.
97. Jiang J, Yuan X, Zhao H, Yan X, Sun X, Zheng Q. Licochalcone A inhibiting proliferation of bladder cancer T24 cells by inducing reactive oxygen species production. Biomed Mater Eng. 2014;24(1):1019–25.
98. Yuan X, Li D, Zhao H, Jiang J, Wang P, Ma X, et al. Licochalcone A-induced human bladder cancer T24 cells apoptosis triggered by mitochondria dysfunction and endoplasmic reticulum stress. Biomed Res Int. 2013;2013:474272.
99. Baldwin Jr AS. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649–83.
100. Schulze-Osthoff K, Ferrari D, Riehemann K, Wesselborg S. Regulation of NF-kappa B activation by MAP kinase cascades. Immunobiology. 1997;198(1–3):35–49.
101. Gilmore TD. Clinically relevant findings. J Clin Invest. 1997;100(12):2935–6.
102. Li JJ, Westergaard C, Ghosh P, Colburn NH. Inhibitors of both nuclear factor-kappaB and activator protein-1 activation block the neoplastic transformation response. Cancer Res. 1997;57(16):3569–76.
103. Nabel GJ, Verma IM. Proposed NF-kappa B/I kappa B family nomenclature. Genes Dev. 1993;7(11):2063.
104. Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene. 2006;25(51):6680–4.
105. Furusawa J, Funakoshi-Tago M, Tago K, Mashino T, Inoue H, Sonoda Y, et al. Licochalcone A significantly suppresses LPS signaling pathway through the inhibition of NF-kappaB p65 phosphorylation at serine 276. Cell Signal. 2009;21(5):778–85.
106. Furusawa J, Funakoshi-Tago M, Mashino T, Tago K, Inoue H, Sonoda Y, et al. Glycyrrhiza inflata-derived chalcones, licochalcone A, licochalcone B and licochalcone D, inhibit phosphorylation of NF-kappaB p65 in LPS signaling pathway. Int Immunopharmacol. 2009;9(4):499–507.
107. Funakoshi-Tago M, Tanabe S, Tago K, Itoh H, Mashino T, Sonoda Y, et al. Licochalcone A potently inhibits tumor necrosis factor alpha-induced nuclear factor-kappaB activation through the direct inhibition of IkappaB kinase complex activation. Mol Pharmacol. 2009;76(4):745–53.
108. Shen H, Zeng G, Tang G, Cai X, Bi L, Huang C, et al. Antimetastatic effects of licochalcone A on oral cancer via regulating metastasis-associated proteases. Tumour Biol. 2014;35(8):7467–74.
109. Tsai JP, Hsiao PC, Yang SF, Hsieh SC, Bau DT, Ling CL, et al. Licochalcone A suppresses migration and invasion of human hepatocellular carcinoma cells through downregulation of MKK4/JNK via NF-kappaB mediated urokinase plasminogen activator expression. PLoS ONE. 2014;9(1):e86537.
110. Huang HC, Tsai LL, Tsai JP, Hsieh SC, Yang SF, Hsueh JT, et al. Licochalcone A inhibits the migration and invasion of human lung cancer cells via inactivation of the Akt signaling pathway with downregulation of MMP-1/-3 expression. Tumour Biol. 2014 Aug 23. PubMed PMID: 25149157. Epub 2014/08/26. Eng.
111. Yao K, Chen H, Lee MH, Li H, Ma W, Peng C, et al. Licochalcone A, a natural inhibitor of c-Jun N-terminal kinase 1. Cancer Prev Res (Phila). 2014;7(1):139–49. PubMed PMID: 24253317. Epub 2013/11/21. Eng. First to report that licochalcone A directly bound to and inhibited JNK1.
112. Yao K, Cho YY, Bode AM, Vummenthala A, Park JG, Liu K, et al. A selective small-molecule inhibitor of c-Jun N-terminal kinase 1. FEBS Lett. 2009;583(13):2208–12.
113. Chang HJ, Yoon G, Park JS, Kim MH, Baek MK, Kim NH, et al. Induction of apoptosis by the licochalcone E in endothelial cells via modulation of NF-kappaB and Bcl-2 Family. Biol Pharm Bull. 2007;30(12):2290–3.
114. Kwon SJ, Park SY, Kwon GT, Lee KW, Kang YH, Choi MS, et al. Licochalcone E present in licorice suppresses lung metastasis in the 4T1 mammary orthotopic cancer model. Cancer Prev Res (Phila). 2013;6(6):603–13.
115. Kim SS, Lim J, Bang Y, Gal J, Lee SU, Cho YC, et al. Licochalcone E activates Nrf2/antioxidant response element signaling pathway in both neuronal and microglial cells: therapeutic relevance to neurodegenerative disease. J Nutr Biochem. 2012;23(10):1314–23.
116. Lee HN, Cho HJ, Lim Do Y, Kang YH, Lee KW, Park JH. Mechanisms by which licochalcone e exhibits potent anti-inflammatory properties: studies with phorbol ester-treated mouse skin and lipopolysaccharide-stimulated murine macrophages. Int J Mol Sci. 2013;14(6):10926–43.
117. Cho YC, Lee SH, Yoon G, Kim HS, Na JY, Choi HJ, et al. Licochalcone E reduces chronic allergic contact dermatitis and inhibits IL-12p40 production through down-regulation of NF-kappa B. Int Immunopharmacol. 2010;10(9):1119–26.